Recent advances in the management and understanding of macular degeneration

Michael Singer; Sepehr Bahadorani

doi:10.12688/f1000research.10998.1

Recent advances in the management and understanding of macular degeneration

Michael Singer, Sepehr Bahadorani

Department of Ophthalmology

Producción científica: Review article › revisión exhaustiva

16 Citas (Scopus)

Resumen

Current management of age-related macular degeneration (AMD) is directed at intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors for the treatment of wet AMD and supplementation with oral antioxidants for the treatment of dry AMD. In this article, we will review recent clinical trials for the treatment of dry and wet AMD.

Idioma original	English (US)
Número de artículo	519
Publicación	F1000Research
Volumen	6
DOI	https://doi.org/10.12688/f1000research.10998.1
Estado	Published - 2017

ASJC Scopus subject areas

General Immunology and Microbiology
General Pharmacology, Toxicology and Pharmaceutics
General Biochemistry, Genetics and Molecular Biology

Acceder al documento

10.12688/f1000research.10998.1

Otros archivos y enlaces

Citar esto

@article{5b85c32818a942d494905d0db6b85e6d,

title = "Recent advances in the management and understanding of macular degeneration",

abstract = "Current management of age-related macular degeneration (AMD) is directed at intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors for the treatment of wet AMD and supplementation with oral antioxidants for the treatment of dry AMD. In this article, we will review recent clinical trials for the treatment of dry and wet AMD.",

keywords = "Lampalizumab, Macular degeneration, Stem cell",

author = "Michael Singer and Sepehr Bahadorani",

note = "Publisher Copyright: {\textcopyright} 2017 Bahadorani S and Singer M.",

year = "2017",

doi = "10.12688/f1000research.10998.1",

language = "English (US)",

volume = "6",

journal = "F1000Research",

issn = "2046-1402",

publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Recent advances in the management and understanding of macular degeneration

AU - Singer, Michael

AU - Bahadorani, Sepehr

PY - 2017

Y1 - 2017

N2 - Current management of age-related macular degeneration (AMD) is directed at intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors for the treatment of wet AMD and supplementation with oral antioxidants for the treatment of dry AMD. In this article, we will review recent clinical trials for the treatment of dry and wet AMD.

AB - Current management of age-related macular degeneration (AMD) is directed at intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors for the treatment of wet AMD and supplementation with oral antioxidants for the treatment of dry AMD. In this article, we will review recent clinical trials for the treatment of dry and wet AMD.

KW - Lampalizumab

KW - Macular degeneration

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=85018312032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018312032&partnerID=8YFLogxK

U2 - 10.12688/f1000research.10998.1

DO - 10.12688/f1000research.10998.1

M3 - Review article

C2 - 28491291

AN - SCOPUS:85018312032

SN - 2046-1402

VL - 6

JO - F1000Research

JF - F1000Research

M1 - 519

ER -

Recent advances in the management and understanding of macular degeneration

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto